Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-12-20
2005-12-20
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
06977251
ABSTRACT:
The instant application provides means of accelerating cell aging and programed cell death in tumor cells by administration of 3β,17α androstenediol (αAED) or its ethers or esters.
REFERENCES:
patent: 2521586 (1950-09-01), Levy et al.
patent: 2845381 (1958-07-01), Tindall
patent: 3963707 (1976-06-01), Högberg et al.
patent: 4628052 (1986-12-01), Peat
patent: 4652553 (1987-03-01), Hagmann et al.
patent: 4652637 (1987-03-01), Hagmann et al.
patent: 4835147 (1989-05-01), Roberts
patent: 4898694 (1990-02-01), Schwartz et al.
patent: 4942154 (1990-07-01), Durette et al.
patent: 5001119 (1991-03-01), Schwartz et al.
patent: 5028631 (1991-07-01), Schwartz et al.
patent: 5206008 (1993-04-01), Loria
patent: 5461042 (1995-10-01), Loria
patent: 5478566 (1995-12-01), Loria
patent: 5744462 (1998-04-01), Schwartz et al.
patent: 5837269 (1998-11-01), Daynes et al.
patent: 5843932 (1998-12-01), Labrie
patent: 5912240 (1999-06-01), Loria
patent: 6407079 (2002-06-01), Müller et al.
patent: 6642227 (2003-11-01), Cao et al.
patent: 2003/0181434 (2003-09-01), Loria
patent: WO 02/072003 (2002-09-01), None
Carter et al., Chemotherapy of Cancer, Second Edition, 1981, John Wiley & Sons, N.Y., N.Y., pp. 362-365.
Begue et al, “C19Steroides Urinaires Dans Une Luteose Ovarienne Gravidique”Journal of Steroid Biochemistryvol. 8, pp. 737-742 (1977) (English Summary).
Von Lubos Starka et al, “Biogenese von Freiem und Sulfatiertem 7α-Hydroxy-Androstenolon in Zellfraktionen der Rattenleber”,Hoppe-Seyler's Z. Physiol. Chem. Bd. 348, S.293-302 (Mar. 1967) (English Summary).
Bjorkhem et al., “Metabolism of Steroids in Germfree and Conventional Rats Treated with a 3β-Hydroxy-Δ5-Steroid Oxidoreductase Inhibitor”,Eur. J. Biochem. vol. 16, pp. 557-566 (1970).
DeFaye et al., “Microbiologicl 7-and 15-Hydroxylations of C-19 Steroids”,Journal of Steroid Biochemistry, vol. 9, pp. 331-336 (1978).
Adams, J.B., et al., “Enzymic synthesis of steroid sulfates. XIV. Properties of human adrenal steroid alcohol sulfotransferase”,Biochim. Biophys. Acta664(3), 460-8 (1981).
Adams, John, et al., “Adrenal dehydroepiandrosterone and human mammary cancer”,Cancer Res. 38 (11, Pt.2), 4036-40 (1978).
Dehennin, L., et al., “Long-term administration of testosterone enanthate to normal men: Alterations of the urinary profile of androgen metabolites potentially useful for detection of testosterone misuse in sport”,J. Steroid Biochem. Mol. Biol. 44(2), 179-89 (1993).
Huynh, P., et al., “Contrasting effects of alpha- and beta-andrestenediol on oncogenic myeloid cell lines in vitro”,Journal of Leukocyte Biology, vol. 62, pp. 258-267 (1997).
Kohara, H., et al., “Stereospecific removal of the 16 alpha-hydrogen in the biosynthesis of 5, 16-androstadien-3 beta-ol from pregnenolone,”Biochimica et Biophysica Acta, vol. 921, pp. 90-95 (1987).
Mancuso, S., et al., “Amniotic 5-androstene-3 beta, 17 alpha-diol in high risk pregnancy”,J. Steroid Biochem., 95-6 (1980).
Plotz, E., et al., “Enzymic activities related to steroidogenesis in postmenopausal ovaries of patients with and without endometrial carcinoma”,Am. J. Obstet. Gynecol. 99(2), 182-97 (1967).
Ruokonen, A., et al., “Free and sulfate-conjugated neutral steroids in human testis tissue”,Biochemistry, 12(8) 1411-16 (1972).
Rozhin, J., et al., “Endcrine steroid sulfotransferases: Steroid alcohol sulfotransferase from human breast carcinoma cell line MCF-7,”J. Steroid Biochem., vol. 25, No. 6, pp. 973-979 (1986).
Huhtaniemi, I., et al., “Ultrastructural and steroidogenic characteristics of an androgen-producing andrenocortical tumour,”Clinical Endrocrinology, vol. 8, pp. 305-314 (1978).
Kwan, T., et al., “Gas chromatographic-mass spectrometric study of metabolites of C21and C19steroids in neonatal porcine testicular microsomes,”Biochem. J., vol. 227, pp. 909-916 (1985).
Huf, P., et al., “The in vitro biosynthesis of epitestosterone and testosterone from C19steroid precursors in the testis of the lizardtiliqua rugosa, ”General and Comparative Endrocrinology, vol. 75, pp. 280-286 (1989).
Rozhin et al., “Endrocine Steroid Sulfotransferases: Steroid Alcohol Sulfotransferase From Human Breat Carcinoma Cell Line MCF-7,”Steroid Biochem., 1986, pp. 973-979, vol. 25, No. 6.
Pasqualini, “Role of Androgens in Breast Cancer,”J. Steroid Biochem. Molec. Biol., 1993, pp. 167-172, vol. 45, Nos. 1-3.
Segaloff, A., “Testosterone and Miscellaneous Steroids in the Treatment of Advanced Mammary Cancer,”Cancer, vol. 10, pp. 808-812 (1957).
Chang, H., et al, “Suppression of Δ5-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells”,PNAS, vol. 96, pp. 11173-11177, Sep., 1999.
Gustafsson, J., et al, “Steroids in urine from a patient with adrenocortical carcinoma after treatment with op′-DDD”, Steroidologia, 2, pp. 27-37, (1971).
Huynh, P., et al., “17 Alpha androstenediol inhibition of breast tumor cell proliferation in estrogen receptor-positive and—negative cell lines”,Cancer Detection and Prevention, 24(5), pp. 435-444, (2000).
Miyamoto, H., et al, “Δ5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells”,PNAS, vol. 95, pp. 11083-11088, (Sep. 1998).
Oertel, G., et al, “The effects of steroids on glucose-6-phosphate dehydrogenase”,J. Steroid of Biochemistry, vol. 3, pp. 493-496, (1972).
Ruzicka, L., et al, “Sex hormones XIII. Concerning cis-testosterone and other 17-cis-hydroxy derivatives of androstane and androstene”, Helv Chim. Acta 19, pp. 842-845, (1936) (translation from German).
Segaloff, A., et al., “Hormonal therapy in cancer of the breast. II. Effect of methylandrostenediol on clinical course and hormonal excretion”,Cancer, vol. 5(2), pp. 271-274, (Mar. 1952).
Segaloff, A., et al, “Hormonal therapy in cancer of the breast. XI. The effect of dehydroepiandrosterone on clinical course and hormonal excretion”,Cancer, vol. 10(6), pp. 1114-1115, (1957).
Adams, J.B., et al. Enzymic synthesis of steroid sulfates. XII. Isolation of dehydroepiandrosterone sulfotransferase from human adrenals by affinity chromatography,BIochimica or Biophysica Acta567(1) 144-153 1979.
Axelson, M., et al. Changes in the metabolic profile of steroids in urine during ethanol metabolism in man ,Journal of Steroid Biochemistry14(2):155-159 1981.
Ruzicka, L. et al. Sex hormones XIII Preparation of 17-ethyl-testosterone and the 3-trans, 17-cis-diols of androstane and androstane Further contributions on the specificity of the sex hormones,Helv Chim. Acta19:357-365 1936 (translated from German).
Segaloff, A., et al, Hormonal therapy in cancer of the breast. IV. Effect of androstenediol on clinical course and hormonal excretionCancer, 5(6):1179-1181 1952.
LandOfFree
5-androstene-3β, 17α diol as an inhibitor of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-androstene-3β, 17α diol as an inhibitor of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-androstene-3β, 17α diol as an inhibitor of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3520626